|
|
General
|
| |
Clinical Use:
|
CA15-3 is a breast cancer associated antigen. It is increased in 8-20% of patients with localised breast cancer and in 70-90% with metastatic breast cancer. It is also increased in cancers of lung, uterus, stomach and other organs, and in patients with benign breast and liver diseases. CA15-3 is a useful tumour marker in monitoring the clinical course of patients after definitive surgery for breast cancer. It is more sensitive and specific than carcinoembryonic antigen (CEA). In one study localised recurrence of breast cancer resulted in increased CA15-3 in less than 10% of patients. CA15-3 increased before metastatic disease was diagnosed in 71% of patients - the mean lead time was 9.5 months. However, in 29% of patients there was no increase in CA15-3 at the time of diagnosis of metastatic disease - a normal CA15-3, therefore, does not exclude the development of metastatic disease. |
| |
Availability:
|
Samples are tested Monday-Saturday. |
| |
|
| |
Code:
|
C153 |
| |
Handling Instructions (to laboratory):
|
Send sample chilled. |
| |
Hyperlink:
|
|
| |
Reference Interval:
|
<31 kU/L
|
Collection Requirements
|
| |
Container:
|
Serum Sep. Tube-SST (GOLD), |
| |
Sample Type:
|
See container |
| |
Minimum Collection Volume:
|
1mL |
| |
Collection Instructions:
|
|
Processing Requirements
|
| |
Alternate Containers:
|
|
|
|
|
Lithium Heparin-PST (GREEN) |
| |
Processing Instructions:
|
|
| |
Minimum Assay Volume:
|
250uL |
| |
Stability:
|
1 week chilled; 2 months frozen |
| |
Transport Instructions (to testing laboratory):
|
Send sample chilled. |
Testing Locations
|
| |
Performed at:
|
|
Section
|
Department
|
Site
|
Contact Phone
|
| Core |
Biochemistry |
Fiona Stanley Hospital |
6152 8140 |
| Core |
Biochemistry |
QEII Medical Centre |
6383 4093 |
|
Last Updated : 03-10-2020 08:09 |